Vitamin D and Phenylbutyrate Supplementation Does Not Modulate Gut Derived Immune Activation in HIV-1
Dysbiosis and a dysregulated gut immune barrier function contributes to chronic immune activation in HIV-1 infection. We investigated if nutritional supplementation with vitamin D and phenylbutyrate could improve gut-derived inflammation, selected microbial metabolites, and composition of the gut mi...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-07-01
|
Series: | Nutrients |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6643/11/7/1675 |
id |
doaj-f85d4b36b8e640b0b5c716675df41400 |
---|---|
record_format |
Article |
spelling |
doaj-f85d4b36b8e640b0b5c716675df414002020-11-25T01:26:23ZengMDPI AGNutrients2072-66432019-07-01117167510.3390/nu11071675nu11071675Vitamin D and Phenylbutyrate Supplementation Does Not Modulate Gut Derived Immune Activation in HIV-1Catharina Missailidis0Nikolaj Sørensen1Senait Ashenafi2Wondwossen Amogne3Endale Kassa4Amsalu Bekele5Meron Getachew6Nebiat Gebreselassie7Abraham Aseffa8Getachew Aderaye9Jan Andersson10Susanna Brighenti11Peter Bergman12Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Huddinge, 14152 Stockholm, SwedenClinical Microbiomics, 2200 Copenhagen, DenmarkCenter for Infectious Medicine (CIM), F59, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital Huddinge, 14152 Stockholm, SwedenDepartment of Internal Medicine, Faculty of Medicine, Black Lion University Hospital and Addis Ababa University, 1176 Addis Ababa, EthiopiaDepartment of Internal Medicine, Faculty of Medicine, Black Lion University Hospital and Addis Ababa University, 1176 Addis Ababa, EthiopiaDepartment of Internal Medicine, Faculty of Medicine, Black Lion University Hospital and Addis Ababa University, 1176 Addis Ababa, EthiopiaDepartment of Internal Medicine, Faculty of Medicine, Black Lion University Hospital and Addis Ababa University, 1176 Addis Ababa, EthiopiaArmauer Hansen Research Institute (AHRI), 1005 Addis Ababa, EthiopiaArmauer Hansen Research Institute (AHRI), 1005 Addis Ababa, EthiopiaDepartment of Internal Medicine, Faculty of Medicine, Black Lion University Hospital and Addis Ababa University, 1176 Addis Ababa, EthiopiaCenter for Infectious Medicine (CIM), F59, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital Huddinge, 14152 Stockholm, SwedenCenter for Infectious Medicine (CIM), F59, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital Huddinge, 14152 Stockholm, SwedenDivision of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Huddinge, 14152 Stockholm, SwedenDysbiosis and a dysregulated gut immune barrier function contributes to chronic immune activation in HIV-1 infection. We investigated if nutritional supplementation with vitamin D and phenylbutyrate could improve gut-derived inflammation, selected microbial metabolites, and composition of the gut microbiota. Treatment-naïve HIV-1-infected individuals (<i>n</i> = 167) were included from a double-blind, randomized, and placebo-controlled trial of daily 5000 IU vitamin D and 500 mg phenylbutyrate for 16 weeks (Clinicaltrials.gov NCT01702974). Baseline and per-protocol plasma samples at week 16 were analysed for soluble CD14, the antimicrobial peptide LL-37, kynurenine/tryptophan-ratio, TMAO, choline, and betaine. Assessment of the gut microbiota involved 16S rRNA gene sequencing of colonic biopsies. Vitamin D + phenylbutyrate treatment significantly increased 25-hydroxyvitamin D levels (<i>p</i> < 0.001) but had no effects on sCD14, the kynurenine/tryptophan-ratio, TMAO, or choline levels. Subgroup-analyses of vitamin D insufficient subjects demonstrated a significant increase of LL-37 in the treatment group (<i>p</i> = 0.02), whereas treatment failed to significantly impact LL-37-levels in multiple regression analysis. Further, no effects on the microbiota was found in number of operational taxonomic units (<i>p</i> = 0.71), Shannon microbial diversity index (<i>p</i> = 0.82), or in principal component analyses (<i>p</i> = 0.83). Nutritional supplementation with vitamin D + phenylbutyrate did not modulate gut-derived inflammatory markers or microbial composition in treatment-naïve HIV-1 individuals with active viral replication.https://www.mdpi.com/2072-6643/11/7/1675HIV-1vitamin Dphenylbutyrateclinical trialTMAOmicrobiotaLL-37kynurenine/tryptophan ratio |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Catharina Missailidis Nikolaj Sørensen Senait Ashenafi Wondwossen Amogne Endale Kassa Amsalu Bekele Meron Getachew Nebiat Gebreselassie Abraham Aseffa Getachew Aderaye Jan Andersson Susanna Brighenti Peter Bergman |
spellingShingle |
Catharina Missailidis Nikolaj Sørensen Senait Ashenafi Wondwossen Amogne Endale Kassa Amsalu Bekele Meron Getachew Nebiat Gebreselassie Abraham Aseffa Getachew Aderaye Jan Andersson Susanna Brighenti Peter Bergman Vitamin D and Phenylbutyrate Supplementation Does Not Modulate Gut Derived Immune Activation in HIV-1 Nutrients HIV-1 vitamin D phenylbutyrate clinical trial TMAO microbiota LL-37 kynurenine/tryptophan ratio |
author_facet |
Catharina Missailidis Nikolaj Sørensen Senait Ashenafi Wondwossen Amogne Endale Kassa Amsalu Bekele Meron Getachew Nebiat Gebreselassie Abraham Aseffa Getachew Aderaye Jan Andersson Susanna Brighenti Peter Bergman |
author_sort |
Catharina Missailidis |
title |
Vitamin D and Phenylbutyrate Supplementation Does Not Modulate Gut Derived Immune Activation in HIV-1 |
title_short |
Vitamin D and Phenylbutyrate Supplementation Does Not Modulate Gut Derived Immune Activation in HIV-1 |
title_full |
Vitamin D and Phenylbutyrate Supplementation Does Not Modulate Gut Derived Immune Activation in HIV-1 |
title_fullStr |
Vitamin D and Phenylbutyrate Supplementation Does Not Modulate Gut Derived Immune Activation in HIV-1 |
title_full_unstemmed |
Vitamin D and Phenylbutyrate Supplementation Does Not Modulate Gut Derived Immune Activation in HIV-1 |
title_sort |
vitamin d and phenylbutyrate supplementation does not modulate gut derived immune activation in hiv-1 |
publisher |
MDPI AG |
series |
Nutrients |
issn |
2072-6643 |
publishDate |
2019-07-01 |
description |
Dysbiosis and a dysregulated gut immune barrier function contributes to chronic immune activation in HIV-1 infection. We investigated if nutritional supplementation with vitamin D and phenylbutyrate could improve gut-derived inflammation, selected microbial metabolites, and composition of the gut microbiota. Treatment-naïve HIV-1-infected individuals (<i>n</i> = 167) were included from a double-blind, randomized, and placebo-controlled trial of daily 5000 IU vitamin D and 500 mg phenylbutyrate for 16 weeks (Clinicaltrials.gov NCT01702974). Baseline and per-protocol plasma samples at week 16 were analysed for soluble CD14, the antimicrobial peptide LL-37, kynurenine/tryptophan-ratio, TMAO, choline, and betaine. Assessment of the gut microbiota involved 16S rRNA gene sequencing of colonic biopsies. Vitamin D + phenylbutyrate treatment significantly increased 25-hydroxyvitamin D levels (<i>p</i> < 0.001) but had no effects on sCD14, the kynurenine/tryptophan-ratio, TMAO, or choline levels. Subgroup-analyses of vitamin D insufficient subjects demonstrated a significant increase of LL-37 in the treatment group (<i>p</i> = 0.02), whereas treatment failed to significantly impact LL-37-levels in multiple regression analysis. Further, no effects on the microbiota was found in number of operational taxonomic units (<i>p</i> = 0.71), Shannon microbial diversity index (<i>p</i> = 0.82), or in principal component analyses (<i>p</i> = 0.83). Nutritional supplementation with vitamin D + phenylbutyrate did not modulate gut-derived inflammatory markers or microbial composition in treatment-naïve HIV-1 individuals with active viral replication. |
topic |
HIV-1 vitamin D phenylbutyrate clinical trial TMAO microbiota LL-37 kynurenine/tryptophan ratio |
url |
https://www.mdpi.com/2072-6643/11/7/1675 |
work_keys_str_mv |
AT catharinamissailidis vitamindandphenylbutyratesupplementationdoesnotmodulategutderivedimmuneactivationinhiv1 AT nikolajsørensen vitamindandphenylbutyratesupplementationdoesnotmodulategutderivedimmuneactivationinhiv1 AT senaitashenafi vitamindandphenylbutyratesupplementationdoesnotmodulategutderivedimmuneactivationinhiv1 AT wondwossenamogne vitamindandphenylbutyratesupplementationdoesnotmodulategutderivedimmuneactivationinhiv1 AT endalekassa vitamindandphenylbutyratesupplementationdoesnotmodulategutderivedimmuneactivationinhiv1 AT amsalubekele vitamindandphenylbutyratesupplementationdoesnotmodulategutderivedimmuneactivationinhiv1 AT merongetachew vitamindandphenylbutyratesupplementationdoesnotmodulategutderivedimmuneactivationinhiv1 AT nebiatgebreselassie vitamindandphenylbutyratesupplementationdoesnotmodulategutderivedimmuneactivationinhiv1 AT abrahamaseffa vitamindandphenylbutyratesupplementationdoesnotmodulategutderivedimmuneactivationinhiv1 AT getachewaderaye vitamindandphenylbutyratesupplementationdoesnotmodulategutderivedimmuneactivationinhiv1 AT janandersson vitamindandphenylbutyratesupplementationdoesnotmodulategutderivedimmuneactivationinhiv1 AT susannabrighenti vitamindandphenylbutyratesupplementationdoesnotmodulategutderivedimmuneactivationinhiv1 AT peterbergman vitamindandphenylbutyratesupplementationdoesnotmodulategutderivedimmuneactivationinhiv1 |
_version_ |
1725109220502667264 |